The Nuclear Medicine Therapy Centre at Fortis Memorial Research Institute (FMRI) is the Only Centre in India Offering Myeloblative MIBG Therapy for High Risk Neuroblastomas in Children.

MIBG Therapy has been extensively used to treat patients with advanced neuroblastomas – a large study has shown that about 30-40% of children with relapsed neuroblastoma have responded to MIBG Therapy, and this makes it one of the most active agents for relapsed disease. While this therapy does not cure neuroblastoma, I-131 MIBG Therapy allows patients to take control of their disease thereby providing the possibility of prolonged disease stabilisation.